
Now loading...
JM Financial maintains a hold rating on Zydus Lifesciences, setting a target price of Rs 1,090. The quarterly income has dropped by 15.40% from the previous quarter but increased by 19.95% compared to the same quarter last year. Despite facing Asacol HD competition, Zydus Lifesciences’ gradual impact is anticipated, with promoters holding a 74.98% stake.
Now loading...